Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Enzymatic Assay Determines Creatinine in Serum, Plasma, and Urine

By LabMedica International staff writers
Posted on 29 Sep 2008
An enzymatic method for the quantitative determination of creatinine in human serum, plasma, and urine complements current methods by increasing accuracy and reducing interference issues for specific patients. More...
Creatinine measurement is the most commonly used indicator of renal function and is used for monitoring patients with renal failure and those undergoing renal dialysis.

Olympus (Hamburg, Germany) introduced the new enzymatic creatinine assay, which is suitable for use across the range of the company's diagnostic analyzers. The new assay complements the current Jaffe method, providing increased accuracy of creatinine measurements for patients suffering from diabetes, renal failure, liver failure, and hepatitis.

The new assay employs the same calibrators and controls as the current Jaffe method; however, to ensure optimal traceability, new set points for calibrator and target values, as well as ranges for control sera have been assigned. Sold in a kit format, the reagent has improved on board stability of 60 days, a calibration stability of 14 days for serum, and 30 days for urine.

Extremely precise and accurate, the enzymatic assay demonstrates excellent agreement with the gas chromatography/mass spectrometry (GC/MS) reference method. The limit of detection for creatinine using serum settings on an Olympus AU640 analyzer was established at 0.88 µmol/l. The assay meets the [U.S.] national kidney disease education program (NKDEP) guidelines and minimizes errors in calculated glomerular filtration rate (cGFR) calculations

Related Links:
Olympus



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.